Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells

• Main Authors: Joelle C. Boulos (Author), Mohamed E. M. Saeed (Author), Manik Chatterjee (Author), Yagmur Bülbül (Author), Francesco Crudo (Author), Doris Marko (Author), Markus Munder (Author), Sabine M. Klauck (Author), Thomas Efferth (Author)
• Format: Book
• Published: MDPI AG, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Crizotinib was a first generation of ALK tyrosine kinase inhibitor approved for the treatment of <i>ALK</i>-positive non-small-cell lung carcinoma (NSCLC) patients. COMPARE and cluster analyses of transcriptomic data of the NCI cell line panel indicated that genes with different cellular...